Hepatitis Monthly

Published by: Kowsar

Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy

Saleh Sandoughdaran 1 , Seyed Moayed Alavian 1 , 2 , Heidar Sharafi 1 , 2 , Bita Behnava 1 , 2 , Shima Salimi 1 , 2 , Leila Mehrnoush 1 , 2 , Pegah Karimi Elizee 2 and Maryam Keshvari 2 , 3 , *
Authors Information
1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2 Middle East Liver Diseases (MELD) Center, Tehran, IR Iran
3 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran
Article information
  • Hepatitis Monthly: January 01, 2015, 15 (1); e23564
  • Published Online: January 13, 2015
  • Article Type: Research Article
  • Received: September 16, 2014
  • Revised: November 21, 2014
  • Accepted: December 22, 2014
  • DOI: 10.5812/hepatmon.23564

To Cite: Sandoughdaran S, Alavian S M, Sharafi H, Behnava B, Salimi S, et al. Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy, Hepat Mon. 2015 ; 15(1):e23564. doi: 10.5812/hepatmon.23564.

Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010; 8(2): 192-9[DOI][PubMed]
  • 2. Khodaei GH, Farbod N, Saeidi M. Frequency of Thalassemia in Iran and Khorasan Razavi. Int J Pediatr. 2013; 1: 45-50
  • 3. Abolghasemi H, Amid A, Zeinali S, Radfar MH, Eshghi P, Rahiminejad MS, et al. Thalassemia in Iran: epidemiology, prevention, and management. J Pediatr Hematol Oncol. 2007; 29(4): 233-8[DOI][PubMed]
  • 4. Ataei B, Hashemipour M, Kassaian N, Hassannejad R, Nokhodian Z, Adibi P. Prevalence of anti HCV infection in patients with Beta-thalassemia in isfahan-iran. Int J Prev Med. 2012; 3-23[PubMed]
  • 5. Alavian S, Tabatabaei S, Lankarani K. Epidemiology of HCV Infection among Thalassemia Patients in Eastern Mediterranean Countries: a Quantitative Review of Literature. Iran Red Crescent Med J. 2010; 12(4): 365-76
  • 6. Alavian SM, Miri SM, Keshvari M, Elizee PK, Behnava B, Tabatabaei SV, et al. Distribution of hepatitis C virus genotype in Iranian multiply transfused patients with thalassemia. Transfusion. 2009; 49(10): 2195-9[DOI][PubMed]
  • 7. Inati A, Taher A, Ghorra S, Koussa S, Taha M, Aoun E, et al. Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. Br J Haematol. 2005; 130(4): 644-6[DOI][PubMed]
  • 8. Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Karimi Elizee P, et al. Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy. Hepat Mon. 2012; 12(6): 372-81[DOI][PubMed]
  • 9. Bacon BR, Shiffman ML, Mendes F, Ghalib R, Hassanein T, Morelli G, et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology. 2009; 49(6): 1838-46[DOI][PubMed]
  • 10. Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC, et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. The American journal of gastroenterology. 2005; 100(11): 2453-62[DOI]
  • 11. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandao-Mello CE, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med. 2009; 150(8): 528-40[PubMed]
  • 12. Alavian SM, Tabatabaei SV, Behnava B, Mahboobi N. Optimal duration of treatment for HCV genotype 1 infection in slow responders: a meta-analysis. Hepat Mon. 2011; 11(8): 612-9[PubMed]
  • 13. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology. 2007; 46(6): 1688-94[DOI][PubMed]
  • 14. Ide T, Hino T, Ogata K, Miyajima I, Kuwahara R, Kuhara K, et al. A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C. Am J Gastroenterol. 2009; 104(1): 70-5[DOI][PubMed]
  • 15. Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology. 2010; 138(2): 503-1[DOI][PubMed]
  • 16. Andriulli A, Di Marco V, Margaglione M, Ippolito AM, Fattovich G, Smedile A, et al. Identification of naive HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. J Hepatol. 2014; 60(1): 16-21[DOI][PubMed]
  • 17. Van Vlierbergh H, Delanghe JR, De Vos M, Leroux-Roel G, Basl Steering Committee . Factors influencing ribavirin-induced hemolysis. J Hepatol. 2001; 34(6): 911-6[PubMed]
  • 18. Takaki S, Tsubota A, Hosaka T, Akuta N, Someya T, Kobayashi M, et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol. 2004; 39(7): 668-73[DOI][PubMed]
  • 19. Telfer PT, Garson JA, Whitby K, Grant PR, Yardumian A, Hoffbrand AV, et al. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. Br J Haematol. 1997; 98(4): 850-5[PubMed]
  • 20. Harmatz P, Jonas MM, Kwiatkowski JL, Wright EC, Fischer R, Vichinsky E, et al. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica. 2008; 93(8): 1247-51[DOI][PubMed]
  • 21. Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, et al. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol. 2012; 56(1): 34-40[DOI][PubMed]
  • 22. Huang CF, Yeh ML, Huang JF, Yang JF, Hsieh MY, Lin ZY, et al. Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. Antiviral Res. 2012; 93(2): 239-44[DOI][PubMed]
  • 23. Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, et al. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS ONE. 2011; 6(3)[DOI][PubMed]
  • 24. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262): 399-401[DOI][PubMed]
  • 25. Di Marco V, Bronte F, Calvaruso V, Capra M, Borsellino Z, Maggio A, et al. IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica. 2012; 97(5): 679-86[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments